Stocktoria
Quince Therapeutics, Inc. QNCX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-09
Quince Therapeutics, Inc. statistics & valuation
Market cap$15.4M
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Return on assets | -89.8% | -49.6% | -18.7% | -49.7% | -67.5% |
| Return on equity | 235.1% | -188.5% | -36.9% | -51.4% | -75.8% |
| Debt / equity | -0.00× | 0.48× | 0.16× | 0.00× | — |
| Current ratio | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 |
Source: SEC EDGAR filings · CIK 0001662774 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.